<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40768812</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN><JournalIssue CitedMedium="Internet"><Volume>392</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation.</ArticleTitle><Pagination><StartPage>103652</StartPage><MedlinePgn>103652</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpet.2025.103652</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3565(25)39865-4</ELocationID><Abstract><AbstractText>Conversion and prevention of atrial fibrillation (AF) are essential requirements for its treatment. Abnormal leakage of calcium from the sarcoplasmic reticulum via the ryanodine receptor 2 (RyR2) during diastole is considered a major cause of AF. Although catheter ablation has made it possible to stop persistent AF, it does not address recurrence. In this context, we describe the additional pharmacological and antiarrhythmic effects of the RyR2 inhibitor M201-A, including the results of a phase I study. M201-A inhibited G-protein-gated atrial K<sup>+</sup> channel at an IC<sub>50</sub> value of 0.35 &#x3bc;M, which was associated with a 38% increase in the atrial effective refractory period (ERP) and high atrial selectivity with an atrial ERP/ventricular ERP of 5.7. M201-A inhibited rapid component of the delayed rectifier potassium current (IC<sub>50</sub> value of 0.43 &#x3bc;M) but induced only a limited prolongation in the action potential duration in rabbit ventricular cells and human induced pluripotent stem cell-derived cardiomyocytes. M201-A is an R-enantiomer of the active metabolite M201-R of K201. After orally administering 540 mg K201 to patients with AF, the unbound drug concentration of M201-R was 30-fold higher (approximately 15-fold for M201-A) than that of K201, and AF was converted in 6 of the 12 patients (50%) during the first 2 hours following administration. M201-A was the main contributor with a stronger bioactive metabolite than M201-B (S-enantiomer) and M201-R. Furthermore, M201-A was 5-fold more biologically active than K201 in humans due to protein binding rates. These pharmacological properties hold promise as a new therapeutic strategy for AF, particularly the prevention of recurrence after catheter ablation. SIGNIFICANCE STATEMENT: Abnormal leakage of calcium from the sarcoplasmic reticulum via the ryanodine receptor 2 (RyR2) is considered a major cause of atrial fibrillation (AF). M201-A had inhibitory effects on RyR2 and G-protein-gated atrial K<sup>+</sup> channel. It had high atrial selectivity with limited QT interval corrected by Fridericia's formula prolongation and proarrhythmic risk. It was the most active conversion metabolite when K201 was administered orally in patients with paroxysmal AF. These pharmacological effects of M201-A, combined with its inhibitory actions on RyR2, provide a promising therapeutic option for treating AF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Noboru</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dokkyo Medical University, Tochigi, Japan; AETAS Pharma Co, Ltd, Tokyo, Japan. Electronic address: kanekon@dokkyomed.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Godfrey L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom. Electronic address: Godfrey.Smith@glasgow.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loughrey</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom. Electronic address: Christopher.Loughrey@glasgow.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Ryuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan; Nojima Hospital, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusano</LastName><ForeName>Kengo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otani</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dokkyo Medical University Nikko Medical Center, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Kayley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Silva Costa</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mark</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinozaki</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kambayashi</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Elspeth B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Charlotte S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitai</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasunuma</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Trial Center, Kitasato University Kitasato Institute Hospital, Kanagawa Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimamoto</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sendai Cardiovascular Center, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Toshiya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tomoni Kangaeru Clinic Honjo Waseda, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Migaku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyoda</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumagai</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Heart Rhythm Center, Fukuoka Sanno Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Isao</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kihara</LastName><ForeName>Yasuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Kobe City Medical Center General Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumagai</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Kitasato University, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Kunio</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AETAS Pharma Co, Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0I621Y6R4Q</RegistryNumber><NameOfSubstance UI="C109183">K201 compound</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013841">Thiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013841" MajorTopicYN="N" AutoHM="Y">Thiazepines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheter ablation</Keyword><Keyword MajorTopicYN="N">Fridericia's corrected QT interval</Keyword><Keyword MajorTopicYN="N">Paroxysmal atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Persistent atrial fibrillation</Keyword><Keyword MajorTopicYN="N">RyR2</Keyword><Keyword MajorTopicYN="N">Torsades de pointes</Keyword></KeywordList><CoiStatement>Conflict of interest The nonclinical and clinical trials conducted by AETAS Pharma Co, Ltd were funded by the Japan Agency for Medical Research and Development. Noboru Kaneko, Ryuko Matsuda, Masashi Toda, Makoto Shinozaki, Toshihiko Fujiwara, Toshiya Sakai, and Kunio Iwata were employees of AETAS Pharma Co, Ltd. The University of Glasgow, with which Christopher M. Loughrey, Godfrey L. Smith, Kayley Scott, Ana Da Silva Costa, Sara Dobi, Alexandra Riddell, Elspeth B. Elliott, and Charlotte S. McCarroll are affiliated, also received funding from AETAS Pharma Co, Ltd. Noboru Kaneko reports financial support was provided by Japan Agency for Medical Research and Development. Noboru Kaneko has patent #OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION PREPARED USING SAME issued to Noboru Kaneko. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40768812</ArticleId><ArticleId IdType="doi">10.1016/j.jpet.2025.103652</ArticleId><ArticleId IdType="pii">S0022-3565(25)39865-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>